Ring Is Alcohol Moiety Patents (Class 514/548)
-
Patent number: 6410781Abstract: Disclosed are compounds which bind &agr;4&bgr;7 integrin. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by &agr;4&bgr;7 integrin. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: February 28, 2000Date of Patent: June 25, 2002Assignee: Elan Pharmaceuticals, Inc.Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett
-
Publication number: 20020077348Abstract: A single dosage medication formulation has a beta-adrenergic blocker and a cholesterol lowering agent that is a statin combined in a single oral formulation for treatment of and reducing the risk of cardiovascular disease to enhance simplicity, cost reduction, convenience, and patient compliance with the use of these agents.Type: ApplicationFiled: February 15, 2002Publication date: June 20, 2002Inventors: Herbert M. Dean, Robert E. Weinstein, Allan M. Weinstein
-
Publication number: 20020065310Abstract: Use of nordihydroguaiaretic derivatives to suppress CDC-2 and survivin, stimulate apoptosis, and treat tumors.Type: ApplicationFiled: May 9, 2001Publication date: May 30, 2002Inventors: Ru Chih C. Huang, Jonathan D. Heller, Chih-Chuan Chang
-
Patent number: 6391916Abstract: Novel C3-substituted cyclodeca-1,5-diynes can be prepared through novel synthetic procedures using starting (E)-C3-substituted-4-(aryl- or heteroarylmethylidene)cyclodeca-1,5-diynes reagents. Both the C3-substituted cyclodeca-1,5-diyn-3-enes and the starting reagents have improved thermal stability compared to unsubstituted counterparts.Type: GrantFiled: July 21, 2000Date of Patent: May 21, 2002Assignee: The Hong Kong University of Science and TechnologyInventors: Wei-Min Dai, Anxin Wu, Yuk Ha Lee, Wataru Hamaguchi, Sei-ichi Nishimoto, Ling Zhou, Atsushi Ishii
-
Publication number: 20020044981Abstract: A polyunsaturated fatty acid-containing composition for treating hypertriglyceridemia and methods of use thereof are provided.Type: ApplicationFiled: April 5, 2001Publication date: April 18, 2002Inventor: Marc E. Surette
-
Patent number: 6365626Abstract: The invention provides BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising BTK inhibitors.Type: GrantFiled: December 7, 2000Date of Patent: April 2, 2002Assignee: Parker Hughes InstituteInventors: Fatih M. Uckun, Yaguo Zheng, Sutapa Ghosh
-
Publication number: 20020032177Abstract: The present invention relates to the use of D-chiro-inositol (DCI) as a regulator of hypothalamic gene expression and, more particularly, to the use of DCI and derivatives and metabolites thereof to treat neuroendocrine impairments such as obesity, polycystic ovarian syndrome (PCOS), impaired regulation of hormones during aging and to correct such neuroendocrine impairments and associated functions.Type: ApplicationFiled: April 30, 2001Publication date: March 14, 2002Applicant: Insmed Pharmaceuticals, Inc.Inventors: Geoffrey Allan, Charles V. Mobbs
-
Patent number: 6355673Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involvedType: GrantFiled: October 18, 2000Date of Patent: March 12, 2002Assignee: Aventis Pharma Deutschland GmbHInventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Bernhard Neises, Günter Billen
-
Publication number: 20020013259Abstract: This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic methods for detecting diseases associated with an autoantigen response to hTM in affected tissue.Type: ApplicationFiled: February 8, 2001Publication date: January 31, 2002Inventor: Kiran M. Das
-
Publication number: 20010056118Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.Type: ApplicationFiled: February 26, 2001Publication date: December 27, 2001Inventors: Amy E. Wright, Jennifer L. Cummins, Shirley A. Pomponi, Ross E. Longley, Richard A. Isbrucker
-
Publication number: 20010051644Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.Type: ApplicationFiled: June 21, 2001Publication date: December 13, 2001Inventor: James Harrison Aylward
-
Publication number: 20010039294Abstract: The interconversion of inactive 11-keto steroids with their active 11&bgr;-hydroxy equivalents can be controlled by the use of inhibitors of the 11&bgr;-reductase enzyme, such as carbenoxolone (3&bgr;-(3-carboxypropionyloxy)-11-oxo-olean-2-en30-oic acid). Such inhibitors may be put to a number of therapeutic uses in humans and animals, for instance to inhibit hepatic gluconeogenesis, to lower intracellular cortisol concentration, to increase insulin sensitivity in adipose tissue and muscle, and to prevent or reduce neuronal loss/cognitive impaiment due to glucocorticoid potentiated neurotoxicity or neural dysfunction or damage.Type: ApplicationFiled: February 27, 1998Publication date: November 8, 2001Inventors: BRIAN ROBERT WALKER, CHRISTOPHER RICHARD W. EDWARDS, JONATHAN ROBERT SECKL
-
Patent number: 6313169Abstract: The present invention provides an antioxidant carotenoid composition substantially free of lutein comprising lutein esters. This antioxidant composition may readily be formulated into products for administration to humans to provide protection from the harmful effects of free radicals. The invention also provides a method of preventing or inhibiting the harmful effects of free radicals by administering an effective amount of an antioxidant carotenoid composition substantially free of lutein comprising lutein esters.Type: GrantFiled: March 16, 2000Date of Patent: November 6, 2001Inventors: Phyllis E. Bowen, James P. Clark
-
Patent number: 6303652Abstract: The invention provides BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising BTK inhibitors.Type: GrantFiled: March 19, 1999Date of Patent: October 16, 2001Assignee: Hughes InstituteInventors: Fatih M. Uckun, Yaguo Zheng, Sutapa Ghosh
-
Publication number: 20010027212Abstract: Poly(ethylene glycol) carbamate derivatives useful as water-soluble pro-drugs are disclosed. These degradable poly(ethylene glycol) carbamate derivatives also have potential applications in controlled hydrolytic degradation of hydrogels. In such degradable hydrogels, drugs may be either trapped in the gel and released by diffusion as the gel degrades, or they may be covalently bound through hydrolyzable carbamate linkages. Hydrolysis of these carbamate linkages releases the amine drug at a controllable rate as the gel degrades.Type: ApplicationFiled: April 26, 2001Publication date: October 4, 2001Applicant: Shearwater CorporationInventors: Michael David Bentley, Xuan Zhao
-
Publication number: 20010025056Abstract: Glycation, particularly of proteins, notably of the skin and/or nails and/or hair of an individual subject in need of such treatment, especially for combating skin aging, comprises administering thereto, for such period of time as required to elicit the desired cosmetic/therapeutic response, a thus-effective amount of at least one hydroxystilbene compound, e.g., of 3,3′,5,5′-tetrahydroxystilbene or derivative thereof.Type: ApplicationFiled: December 20, 2000Publication date: September 27, 2001Inventor: Jean Maignan
-
Patent number: 6294575Abstract: The invention provides BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising BTK inhibitors.Type: GrantFiled: October 16, 2000Date of Patent: September 25, 2001Assignee: Parker Hughes InstituteInventors: Fatih M. Uckun, Yaguo Zheng, Sutapa Ghosh
-
Patent number: 6294585Abstract: Disclosed are methods for increasing the differentiation of mammalian neuronal cells for purposes of treating neurodegenerative diseases or nerve damage by administration of various compounds including alcohols, diols and/or triols and their analogues.Type: GrantFiled: September 18, 1997Date of Patent: September 25, 2001Assignee: Applied Genetics Incorporated DermaticsInventor: David A. Brown
-
Patent number: 6291524Abstract: A method for suppressing undesired viral growth in a host which comprises administering to the host an effective amount of a compound of the formula: wherein R1, R2, R3 and R4 are independently selected from the group consisting of HO—, CH3O— and CH3(C═O)O—. The method is exemplified by inhibiting Tat transactivation of a lentivirus and in suppressing Herpes simplex virus.Type: GrantFiled: June 25, 1997Date of Patent: September 18, 2001Assignee: Johns Hopkins UniversityInventors: Ru Chih C. Huang, John N. Gnabre
-
Patent number: 6228886Abstract: A nutritional formulation containing bactericidal amounts of diacetyltartaric acid esters of mono- and diglycerides is provided. A process of inhibiting bacterial infections including the step of feeding the nutritional composition to a subject is also provided.Type: GrantFiled: May 22, 2000Date of Patent: May 8, 2001Assignee: Abbott LaboratoriesInventors: Steven N. Anderson, Milo Duane Hilty, Terry Bruce Mazer, Joseph Schaller, Melinda Guzman-Harty, Theresa Siu-Ling Wai Lee, Lisa Ann Reaves, Jin-Zhou Liu
-
2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
Patent number: 6214873Abstract: The present invention relates to a compound of the general formula wherein R1, R2, R3 and R4 are each a hydrogen or an acyl, a pharmaceutically acceptable acid addition salt thereof or a hydrate thereof; a pharmaceutical comprising this compound; a pharmaceutical composition comprising this compound and a pharmaceutically acceptable carrier; and 2-amino-2-(2-(4-(1-hydroxy-5-phenylpentyl)phenyl)ethyl)propane-1,3-diol or 2-amino-2-(2-(4-formylphenyl)ethyl)propane-1,3-diol, the derivatives of the two compounds whose amino group and/or hydroxy group are(is) protected or a salt thereof. The compound of the present invention shows superior immunosuppressive action with less toxicity and higher safety, and is useful as a drug for prevention or suppression of rejection of organs or bone marrow transplantation, or as a drug for prevention or treatment of various autoimmune diseases or allergic diseases.Type: GrantFiled: January 5, 2000Date of Patent: April 10, 2001Assignee: Welfide CorporationInventors: Kunitomo Adachi, Yoshiyuki Aoki, Tokushi Hanano, Koji Teshima, Yukio Hoshino, Tetsuro Fujita -
Patent number: 6197818Abstract: The present invention relates new use of rhein or the salt thereof, that is new use in preparing medicine for treatment of diabetic nephropathy. A medicine containing rhein or the salt thereof for treatment of diabetic nephropathy may be supplied in aqueous solution or capsula for oral, the dosage is not larger than 200 mg/day. Toxicity of rhein or the salt thereof is low, LD50 is 3.2 g/kg. The concentration of medicine in blood is still higher in 24 hours after administered rhein by oral. Rhein can effectively control or decrease the hyperglycemia, suppress renal hypertrophy and kidney index in experimental diabetic rats. The urinary protein execretion was significantly decreased in the diabetic patients treated by rhein.Type: GrantFiled: October 25, 1999Date of Patent: March 6, 2001Assignee: Nanjing General Hospital of Nanjing Command, PLAInventor: Leishi Li
-
Patent number: 6180669Abstract: A compound effect for the treatment of dermatological disorders comprises a mono- or diester of an &agr;,&ohgr;-dicarboxylic acid, wherein the alcohol moiety of the said ester comprises a keratolytically active alcohol. The compound may have the formula, where n is in the range of 6 to 12; m is in the range of 0 to 8; R′ is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR″, CONHR″ and COOR″; R″ is selected from the group consisting of alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.Type: GrantFiled: April 5, 1999Date of Patent: January 30, 2001Assignee: Tamarkin Pharmaceutical Innovation Ltd.Inventor: Dov Tamarkin
-
Patent number: 6172110Abstract: Betulin and dihydrobetulin acyl derivatives according to the present invention have been found to have potent anti-HIV activity. The compounds of the present invention have the following formulae: or pharmaceutically acceptable salts thereof, wherein R1 is a C2-C20 substituted or unsubstituted carboxyacyl, R2 is a C2-C20 substituted or unsubstituted carboxyacyl; and R3 is hydrogen, halogen, amino, optionally substituted mono- or di-alkylamino, or —OR4, where R4 is hydrogen, C1-4 alkanoyl, benzoyl, or C2-C20 substituted or unsubstituted carboxyacyl; wherein the dashed line represents an optional double bond between C20 and C29.Type: GrantFiled: March 2, 1999Date of Patent: January 9, 2001Assignees: The University of North Carolina at Chapel Hill, BBI Biotech Research Laboratories, Inc.Inventors: Kuo-Hsiung Lee, I-Chen Sun, Hui-Kang Wang, Louis Mark Cosentino
-
Patent number: 6160010Abstract: The invention provides BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising BTK inhibitors.Type: GrantFiled: July 22, 1999Date of Patent: December 12, 2000Assignee: Parker Hughes InstituteInventors: Fatih M. Uckun, Yaguo Zheng, Sutapa Ghosh
-
Patent number: 6147250Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.Type: GrantFiled: May 14, 1998Date of Patent: November 14, 2000Assignee: AtheroGenics, Inc.Inventor: Patricia K. Somers
-
Patent number: 6140361Abstract: 2-Deoxystreptamine is an aminocyclitol whose structural stability and abundant functionality make it an attractive scaffold for the combinatorial generation of small molecules. The ability to selectively functionalize the various positions of 2-deoxystreptamine with an almost infinite number of different groups ensures that the libraries so generated will be both spatially and functionally diverse. These compounds can then be screened for biological activity to afford lead compounds for pharmaceutical programs. Additionally, biological ligand mimics based on 2-deoxystreptamine can be readily appended, either directly or through a tether, to solid surfaces or incorporated covalently into gels to afford novel materials useful in separation science.Type: GrantFiled: March 22, 1999Date of Patent: October 31, 2000Assignee: Scriptgen Pharmaceuticals, Inc.Inventors: Gary R. Gustafson, David G. Powers, Mark A. Wuonola
-
Patent number: 6133261Abstract: The invention provides a therapeutic method for treating or preventing stroke and other ischemic disorders, as well as novel compounds and pharmaceutical compositions useful for carrying out such methods.Type: GrantFiled: July 15, 1998Date of Patent: October 17, 2000Assignee: Research Corporation Technologies, Inc.Inventor: Robert H. Harris
-
Patent number: 6127417Abstract: New stable derivatives of ubiquinole are described, having general formula (I), along with processes for their production and their pharmaceutical use, in particular in the treatment of intracellular oxidative stress and diseases involving oxidative stress of this kind.Type: GrantFiled: August 3, 1999Date of Patent: October 3, 2000Assignee: IDI Farmaceutici S.p.A.Inventors: Decimo Guarnieri, Santo Carbone, Siro Passi
-
Patent number: 6124359Abstract: Methods and compositions for the control of nematodes are disclosed. Specifically, fatty acid ester compounds have been found to advantageously control nematodes at concentrations which are non-phytoxic. The fatty acid ester compounds can be used in conjunction with other nematicidal agents such as free fatty acids, fatty acid salts, avermectins, ivermectin, and milbemycin. In another embodiment, the subject invention further provides methods for killing the eggs of nematodes. Thus, the subject invention further relates to the surprising discovery that certain fatty acid esters have ovicidal activity against nematode eggs.Type: GrantFiled: December 12, 1997Date of Patent: September 26, 2000Assignee: Mycogen CorporationInventors: Jerald S. Feitelson, Charles J. Dullum
-
Patent number: 6124358Abstract: Provided is a pharmaceutical composition based on rhein or diacerhein. The composition is intended for administration by the oral, rectal or cutaneous (percutaneous or transdermal) route, and comprises rhein or diacerhein, or one of their pharmaceutically acceptable salts or esters, and sodium lauryl sulfate, comicronized, in a weight ratio between 3:1 and 30:1. The composition exhibits improved bioavailability.Type: GrantFiled: August 20, 1998Date of Patent: September 26, 2000Assignee: Mazal Pharmaceutique (SARL)Inventors: Cyril Estanove, Alain Prudhomme
-
Patent number: 6121319Abstract: This invention is a method and composition for the inhibition of VCAM-1, and in particular for the treatment of cardiovascular or inflammatory disease, including atherosclerosis, that includes the administration of an effective amount of an ester of probucol.Type: GrantFiled: May 14, 1998Date of Patent: September 19, 2000Assignee: AtheroGenics, Inc.Inventor: Patricia K. Somers
-
Patent number: 6080739Abstract: The present invention relates to colchicine and thiocolchicine derivatives which can be obtained from these molecules by functionalization of the C-7 to ketone or functionalization of the amino group. Said compounds have a marked antiblastic activity both on the normal cancer cells and on the chemoresistant phenotype. The compounds of the invention can be administered both by injection and orally.Type: GrantFiled: November 24, 1998Date of Patent: June 27, 2000Assignee: Indena S.p.A.Inventor: Ezio Bombardelli
-
Patent number: 6071923Abstract: This invention relates to the novel retinoyloxy(aryl-substituted)-alkylene butyrate compounds of Formula (I) and pharmaceutical compositions containing same, to methods of treating, preventing or ameliorating cancer and other proliferative diseases in a subject in need of such treatment comprising administering a compound of Formula (I) and pharmaceutically-acceptable salts and prodrugs thereof. ##STR1## The compounds of the invention are also useful in methods of inhibiting histone deacetylase, ameliorating wrinkles, treating or ameliorating dermatological disorders, inducing wound healing, treating cutaneous ulcers and treating gastrointestinal disorders.Type: GrantFiled: June 26, 1997Date of Patent: June 6, 2000Assignees: Bar-Ilan University, Mor Rese ApplicationsInventors: Abraham Nudelman, Ada Rephaeli
-
Patent number: 6066669Abstract: A nutritional formulation containing bacterial amounts of diacetyltartaric acid esters of mono- and diglycerides is provided. A process of inhibiting bacterial infections including the step of feeding the nutritional composition to a subject is also provided.Type: GrantFiled: April 16, 1999Date of Patent: May 23, 2000Assignee: Abbott LaboratoriesInventors: Steven N. Anderson, Milo Duane Hilty, Terry Bruce Mazer, Joseph Schaller, Melinda Guzman-Harty, Theresa Siu-Ling Wai Lee, Lisa Ann Reaves, Jin-Zhou Liu
-
Patent number: 6054479Abstract: Therapeutic treatment as well as prophylactic measures are provided by topical application of compositions containing an aryl 2-acetoxyethanoic acid to eradicate or prevent the development of axillary foul odor, foot malodor and other body odors, e.g. scalp, and skin, nail and follicular infections caused by microorganisms. The compositions are antimicrobial against several organisms that infect the skin and are specifically effective against P. acnes. The compositions are therapeutically effective against folliculitis and perifolliculitis and are useful for other skin lesions, nail and mucosal infections such as impetigo, seborrheic dermatitis, erythrasma and trichomycosis axillaris, associated with or caused by microorganisms. The therapeutic effect of the composition may be synergized or amplified by incorporating a cosmetic or dermatologic agent into the formulation for topical treatment of cosmetic and dermatologic indications.Type: GrantFiled: June 28, 1999Date of Patent: April 25, 2000Assignee: Tristrata, Inc. (A Delaware Corporation)Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Patent number: 6046238Abstract: Therapeutic treatment as well as prophylactic measures are provided by topical application of compositions containing an aryl 2-acetoxyethanoic acid to eradicate or prevent the development of axillary foul odor, foot malodor and other body odors, e.g. scalp, and skin, nail and follicular infections caused by microorganisms. The compositions are antimicrobial against several organisms that infect the skin and are specifically effective against P. acnes. The compositions are therapeutically effective against folliculitis and perifolliculitis and are useful for other skin lesions, nail and mucosal infections such as impetigo, seborrheic dermatitis, erythrasma and trichomycosis axillaris, associated with or caused by microorganisms. The therapeutic effect of the composition may be synergized or amplified by incorporating a cosmetic or dermatologic agent into the formulation for topical treatment of cosmetic and dermatologic indications.Type: GrantFiled: June 28, 1999Date of Patent: April 4, 2000Assignee: TriStrata, Inc.Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Patent number: 6043277Abstract: This invention relates to the novel compounds of Formula (I) and pharmaceutical compositions containing same, to methods of treating, preventing or ameliorating cancer and other proliferative diseases in a subject in need of such treatment comprising administering a compound of Formula (I) and pharmaceutically-acceptable salts and prodrugs thereof. ##STR1## The compounds of the invention are also useful in methods of ameliorating wrinkles, inducing wound healing, treating cutaneous ulcers and treating gastrointestinal disorders.Type: GrantFiled: October 6, 1997Date of Patent: March 28, 2000Assignees: Bar-Ilan University, Kupat Holim Health Institution of the General Federation of LaborInventors: Ada Rephaeli, Abraham Nudelman
-
Patent number: 6040342Abstract: This invention relates to the novel compounds of Formula (I) and pharmaceutical compositions containing same, to methods of treating, preventing or ameliorating cancer and other proliferative diseases in a subject in need of such treatment comprising administering a compound of Formula (I) and pharmaceutically-acceptable salts and prodrugs thereof. ##STR1## The compounds of the invention are also useful in methods of ameliorating wrinkles, inducing wound healing, treating cutaneous ulcers and treating gastrointestinal disorders.Type: GrantFiled: July 2, 1996Date of Patent: March 21, 2000Assignees: Bar-Ilan University, Kupat Holim Health Institution of the General Federation of LaborInventors: Ada Rephaeli, Abraham Nudelman
-
Patent number: 6037369Abstract: The instant invention provides compositions containing molecules having at least one moiety from .beta.(3,4-dihydroxyphenyl) lactic acid and/or caffeic acid which are found in extracts from genus Salvia, said moieties being of the formula: ##STR1## said active agents having a molecular weight of at least 190 daltons. A class of preferred agents are those which are conjugated to form dimers and larger polymers containing said moieties. The agents of the invention may be administered in pharmaceutically acceptable carriers systemically or locally.Type: GrantFiled: June 25, 1998Date of Patent: March 14, 2000Assignee: Georgetown University School of MedicineInventors: Myun K. Han, Paul Lee
-
Patent number: 6022895Abstract: Substituted amino compounds of general formula (I) ##STR1## are described, as are a method of preparing them and their use as drugs, especially as analgesics.Type: GrantFiled: March 11, 1998Date of Patent: February 8, 2000Assignee: Gruenenthal GmbHInventors: Oswald Zimmer, Wolfgang Werner Alfred Strassburger, Helmut Heinrich Buschmann, Werner Englberger, Elmar Josef Friderichs
-
Patent number: 6015832Abstract: Methods for inactivating bacteria including bacterial spores using an oil-in-water emulsion are provided. The oil-in-water emulsion comprises an oil, a surfactant and an organic phosphate-based solvent. These methods can be used to inactivate a wide variety of bacteria such as Bacillus.Type: GrantFiled: December 31, 1997Date of Patent: January 18, 2000Assignee: The Regents of the University of MichiganInventors: James R. Baker, Jr., D. Craig Wright, Michael M. Hayes, Tarek Hamouda, Joan Brisker
-
Patent number: 6013836Abstract: This invention relates to N'-substituted-N,N'-disubstitutedhydrazines of formula I ##STR1## wherein X and X' are independently O, S, or NR; A' and B' are independently substituted or unsubstituted aryl or aromatic heterocycle; wherein F is alkyl, alkenyl, or aralkyl; and wherein E is a tertiary carbon containing organic radical having a total of at least four carbon and halogen atoms but not more than six halogen atoms, or a non-tertiary carbon containing non-haloalkyl organic or organometallic radical having at least five atoms other than hydrogen, oxygen and halogen which are useful as insecticides, compositions containing those compounds, methods of producing the compounds, and methods of their use. More particularly, the invention relates to insect growth regulating compounds and compositions, and methods of using such compounds and compositions. Compounds of the present invention are particularly suitable for controlling plant-destructive insects in crops of cultivated plants, ornamentals and forestry.Type: GrantFiled: May 22, 1995Date of Patent: January 11, 2000Assignee: Rohm and Haas CompanyInventors: Adam Chi-Tung Hsu, Harold Ernest Aller, Dat Phat Le, Donald Wesley Hamp, Barry Weinstein, Raymond August Murphy
-
Patent number: 6010693Abstract: There are disclosed a controlling agent and an antifouling composition against harmful aquatic organisms, which include a particular N-phenylisothiazolone derivative of the formula: ##STR1## wherein X.sup.1 and X.sup.2 are the same or different and are independently hydrogen, chlorine or bromine; and R is haloalkoxy. Also disclosed is a method for preventing or inhibiting the adhesion of harmful aquatic organisms to water-exposed articles, which includes applying the antifouling composition to the water-exposed articles.Type: GrantFiled: March 18, 1997Date of Patent: January 4, 2000Assignees: Chugoku Marine Paints, Ltd., Sumitomo Chemical Company, LimitedInventors: Makoto Tsuboi, Shuhei Yuki, Akiko Kakimizu, Kenji Arai, Masato Mizutani
-
Patent number: 5985923Abstract: The composition for the treatment of poultry litters comprises at least an edible surfactant emulsifying agent, for example an ethoxylate obtained from castor oil. It may also be combined with a mixture of cresols, guaiacol and resorcinol. This composition can be sprayed in liquid form on the litter so as to reduce the effects of coccidiose.Type: GrantFiled: May 13, 1998Date of Patent: November 16, 1999Assignee: Crina S.A.Inventor: Jean Rossi
-
Patent number: 5985927Abstract: Medicinal products for the selective control of tumor tissue and a method for control of such tumor tissue by administration of such product to a host. The products comprise: (a) two different compounds having a pH below 7 when the compounds are present in a protonated form, such compounds having the formula set forth below and (b) a pharmaceutically acceptable inert medicinal product carrier. The compounds have the following ##STR1## wherein R.sub.1 is hydrogen or a moiety which completes an ester group or an ether group, R.sub.2 is independently selected from the group consisting of an amino group, hydroxyl, an ester group, an ether group and a halogen, and n is an integer of 1 to 4.Type: GrantFiled: February 17, 1998Date of Patent: November 16, 1999Inventor: Werner Kreutz
-
Patent number: 5981791Abstract: A new salt of a prodrug useful in antibody directed enzyme prodrug therapy (ADEPT) is disclosed. A hydrogen iodide salt of the prodrug N-(4-[N,N-bis(2-iodoethyl)amino]phenoxycarbonyl)-L-glutamic acid is prepared which can be obtained in crystalline form. Preparation of the crystalline form of the prodrug enables preparation of the prodrug in highly pure form.Type: GrantFiled: June 23, 1997Date of Patent: November 9, 1999Assignee: Zeneca LimitedInventors: David William Heaton, Susan Dines, Robert Ian Dowell
-
Patent number: 5968921Abstract: FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.Type: GrantFiled: October 24, 1997Date of Patent: October 19, 1999Assignee: Orgegon Health Sciences UniversityInventor: Bruce G. Gold
-
Patent number: 5962525Abstract: 6,7-disubstituted-2-aminotetralines of general formula (1) ##STR1## and their pharmacologically acceptable salts, wherein X and Y, identical or different are selected from the group consisting of methoxy, acetoxy and fluoro; and R and R.sub.1, identical or different, are selected from the group consisting of hydrogen, ethyl, propyl, cyclopropylmethyl, 2-hydroxy-2-phenylethyl, 2-hydroxy-2-(4-methylphenyl)ethyl and 2-hydroxy-3-(4-methoxyphenoxy)propyl are endowed with immunomodulator activity.Type: GrantFiled: June 9, 1997Date of Patent: October 5, 1999Assignee: Sigma-TauInventors: Piero Foresta, Mauro Marzi, Maria Ornella Tinti
-
Patent number: RE36520Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are useful as antihypercholesterolemic agents and are represented by the following general structural formula (II): ##STR1##Type: GrantFiled: November 4, 1998Date of Patent: January 18, 2000Assignee: Merck & Co., Inc.Inventors: Robert L. Smith, Wasyl Halczenko, George D. Hartman, Gerald E. Stokker, Edward S. Inamine, Otto D. Hensens, David R. Houck, Ta Jyh Lee